Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: A meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Zhong, Jian Hong ^a   You, Xue Mei ^a   Gong, Wen Feng ^a   Ma, Liang ^a   Zhang, Yu ^a   Mo, Qin Guo ^a   Wu, Liu Cheng ^a   Xiao, Jun ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; CANCER RISK; CAUCASIAN; CHINESE; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR GENE; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LIVER CELL CARCINOMA; ONCOGENE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; CASE CONTROL STUDY; ETHNOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HOSPITAL; LIVER TUMOR; META ANALYSIS; PUBLISHING;

EPIDERMAL GROWTH FACTOR;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; EPIDERMAL GROWTH FACTOR; GENETIC PREDISPOSITION TO DISEASE; HOSPITALS; HUMANS; LIVER NEOPLASMS; POLYMORPHISM, GENETIC; PUBLICATION BIAS;

EID: 84863268589     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032159     Document Type: Review

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Nordenstedt H, White DL, El-Serag HB, (2010) The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 (Suppl 3): S206-214.
3. Thomas MB, Zhu AX, (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23: 2892-2899.
4. Velazquez RF, Rodriguez M, Navascues CA, Linares A, Pérez R, et al. (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37: 520-527.
5. Coleman WB, (2003) Mechanisms of human hepatocarcinogenesis. Curr Mol Med 3: 573-588.
6. Llovet JM, Burroughs A, Bruix J, (2003) Hepatocellular carcinoma. Lancet 362: 1907-1917.
7. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, et al. (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34: 570-575.
8. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, et al. (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259.
9. Kim CK, Lim JH, Lee WJ, (2001) Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 20: 99-104.
10. Fisher DA, Lakshmanan J, (1990) Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 11: 418-442.
11. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC, et al. (2008) Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology 47: 1702-1713.
12. Mullhaupt B, Feren A, Fodor E, Jones A, (1994) Liver expression of epidermal growth factor RNA. Rapid increases in immediate-early phase of liver regeneration. J Biol Chem 269: 19667-19670.
13. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, et al. (2002) Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359: 397-401.
14. Lanuti M, Liu G, Goodwin JM, Zhai R, Fuchs BC, et al. (2008) A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 14: 3216-3222.
15. Xu W, Li Y, Wang X, Chen B, Liu S, et al. (2010) Association between EGF promoter polymorphisms and cancer risk: a meta-analysis. Med Oncol 27: 1389-1397.
16. Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, et al. (2008) Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299: 53-60.
17. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, et al. (2011) A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 141: 141-149.
18. Chen K, Wei Y, Yang H, Li B, (2011) Epidermal growth factor +61 G/A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Genet Test Mol Biomarkers 15: 251-255.
19. Li Y, Xie Q, Lu F, Zhao J, Mao P, et al. (2010) Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. Liver Int 30: 112-118.
20. Qi P, Wang H, Chen YM, Sun XJ, Liu Y, et al. (2009) No association of EGF 5′UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Pathology 41: 555-560.
21. Wang HX, Xie WM, Zhou GQ, (2009) Epidermal growth factor gene polymorphism associated with susceptibility to hepatocellular carcinoma. Guangxi Medical University. Master Dissertation.
22. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
23. Bitetto D, Cmet S, Fornasiere E, Cussigh A, Fumolo E, et al. (2011) Epidermal growth factor RS4444903 G/G genotype in patients with chronic hepatitis C: Relationship with a worse disease and a more rapid fibrotic evolution. Journal of Hepatology 54 (SUPPL. 1): (S54).
24. Bitetto D, Cmet S, SFornasiere E, Cussigh A, Fumolo E, et al. (2011) Epidermal growth factor rs4444903 G/G genotype in chronic hepatitis C: Relationship with a worse disease and a more rapid fibrotic evolution. Digestive and Liver Disease 43 (SUPPL. 2): (S79).
25. Kovar FM, Thallinger C, Marsik CL, Perkmann T, Puhalla H, et al. (2009) The EGF 61A/G polymorphism- a predictive marker for recurrence of liver metastases from colorectal cancer. Wien Klin Wochenschr 121: 638-643.
26. Qi P, Chen YM, Gao CF, Fang M, Sun XJ, et al. (2008) Relationship between polymorphism of epidermal growth factor 5′UTR Variant G61A gene and hepatocellular carcinoma in patients with chronic hepatitis B virus infection in China. Chin J Biologicals 21: 1051-1053.
27. Llovet JM, Bruix J, (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48: 1312-1327.
28. Bowen DG, Walker CM, (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952.
29. El-Serag HB, Mason AC, (2000) Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160: 3227-3230.
30. Wei Y, Liu F, Li B, Chen X, Ma Y, et al. (2011) Polymorphisms of tumor necrosis factor-alpha and hepatocellular carcinoma risk: a HuGE systematic review and meta-analysis. Dig Dis Sci 56: 2227-2236.
31. Minmin S, Xiaoqian X, Hao C, Baiyong S, Xiaxing D, et al. (2011) Single nucleotide polymorphisms of Toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PLoS One 6: e19466.
32. White DL, Li D, Nurgalieva Z, El-Serag HB, (2008) Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol 167: 377-389.
33. Natarajan A, Wagner B, Sibilia M, (2007) The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci U S A 104: 17081-17086.
34. Komuves LG, Feren A, Jones AL, Fodor E, (2000) Expression of epidermal growth factor and its receptor in cirrhotic liver disease. J Histochem Cytochem 48: 821-830.
35. Breuhahn K, Longerich T, Schirmacher P, (2006) Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25: 3787-3800.
36. Ettinger DS, (2006) Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist 11: 358-373.
37. Tan D, Xu J, Li Y, Lai R, (2010) Association between +61G polymorphism of the EGF gene and glioma risk in different ethnicities: a meta-analysis. Tohoku J Exp Med 222: 229-235.